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Peroxisome proliferator-activated receptor αSystemic deletion of the gene encoding for adipose triglyceride lipase (ATGL) inmice leads to severe cardiac dys-
function due to massive accumulation of neutral lipids in cardiomyocytes. Recently, impaired peroxisome
proliferator-activated receptor α (PPARα) signaling has been described to substantially contribute to the ob-
served cardiac phenotype. Disturbances of the ubiquitin–proteasome system (UPS) have been implicated in nu-
merous cardiac diseases including cardiomyopathy, ischemic heart disease, and heart failure. The objective of the
present study was to investigate the potential role of UPS in cardiac ATGL deﬁciency. Our results demonstrate
prominent accumulation of ubiquitinated proteins in hearts of ATGL-deﬁcient mice, an effect that was abolished
upon cardiomyocyte-directed overexpression of ATGL. In parallel, cardiac protein expression of the ubiquitin-
activating enzyme E1a, which catalyzes the ﬁrst step of the ubiquitination cascade, was signiﬁcantly upregulated
in ATGL-deﬁcient hearts. Dysfunction of the UPS was accompanied by activation of NF-κB signaling. Moreover,
the endoplasmic reticulum (ER)-resident chaperon protein disulﬁde isomerase was signiﬁcantly upregulated
in ATGL-deﬁcient hearts. Chronic treatment of ATGL-deﬁcient micewith the PPARα agonistWy14,643 improved
proteasomal function, preventedNF-κB activation and decreased oxidative stress. In summary, our data point to a
hitherto unrecognized link between proteasomal function, PPARα signaling and cardiovascular disease.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ubiquitin–proteasome system (UPS) represents the major deg-
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. This is an open access article underinvolved in quality control and turnover of cellular proteins (for review,
see [1]). Prior to proteolytic degradation, proteins are tagged by cova-
lent linkage to multiple ubiquitin molecules. This process involves
sequential actions of ubiquitin-activating enzymes (E1), ubiquitin-
conjugating enzymes (E2), and ubiquitin-ligases (E3). Degradation of
ubiquitinated proteins is mediated by the 26S proteasome, an ATP-
dependent proteolytic complex that consists of a 20S core and two
19S regulatory subunits. Effective quality control and protein turnover
in the heart are crucial for physiological cardiac performance and dys-
function of the UPS has been implicated in numerous cardiac diseases
including cardiomyopathy, ischemic heart disease, and heart failure
[2–4]. In studies of ischemia/reperfusion (I/R) injury, decreased
proteasomal activity was associated with oxidative modiﬁcation of the
20S proteasome [5]. In a transgenicmousemodel of desmin-related car-
diomyopathy, entry of ubiquitinated proteins into the 20S proteasome
was blocked due to the downregulation of key components of the 19S
subunit [6]. Furthermore, proteasomal inhibition was described to dis-
turb mitochondrial homeostasis, resulting in impaired mitochondrial
electron transport and therefore decreased energy production [7]. In a
mouse model of pressure overload-induced cardiac hypertrophy, dys-
function of the UPS was linked to an imbalance of apoptosis regulating
proteins, e.g. elevation of apoptotic signals (p53 and Bax) and/orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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transition from decompensated cardiac hypertrophy to decompensated
heart failure [3] was observed in those animals, indicating a possible
role of UPS in development of cardiac dysfunction.
Peroxisome proliferator-activated receptor α (PPARα) acts as key
transcriptional regulator of lipid and glucose metabolism and is impli-
cated in the pathogenesis of inﬂammatory processes. PPARα is predom-
inantly expressed in tissues with high intracellular fatty acid (FA)
catabolism, such as the liver, skeletal muscle, and heart. Activation of
PPARα by FA or FA derivates results in heterodimerization with nuclear
retinoid X receptor and recruitment of PPARγ coactivator-1α (PCG-1α)
or PPARγ coactivator 1-ß (for review, see [8]). Haemmerle and
colleagues have recently shown that generation of PPARα ligands by
the lipolytic enzyme adipose triglyceride lipase (ATGL) is pivotal for
efﬁcient mitochondrial substrate oxidation and respiration [9]. The
enzyme is predominantly expressed in adipose tissues and catalyzes
the initial and rate-limiting step of triglyceride (TAG) hydrolysis [10].
Global deletion of the ATGL gene in mice resulted in a phenotype with
massive cardiac lipid accumulation, leading to severe cardiomyopathy
and premature death of the animals [11]. Pharmacological treatment
of ATGL-deﬁcient (AKO) mice with PPARα agonists ameliorated mito-
chondrial defects and prevented lethal cardiomyopathy [9]. Langendorff
perfusion experiments of isolated hearts showed that chronic treatment
of AKOmicewith a PPARα agonist effectively attenuated cardiac hyper-
trophy and improved systolic and diastolic performance [12]. A recent
study by Schrammel and colleagues pointed to an essential role of
oxidative and inﬂammatory stress in cardiac dysfunction observed in
ATGL deﬁciency [13]. These observations agree well with a report show-
ing the involvement of oxidative stress in left ventricular dysfunction ob-
served in PPARα-deﬁcient mice [14]. In addition to their lipid lowering
actions, PPARα agonists were shown to prevent cardiac inﬂammation
in angiotensin II-infused rats via inhibition of the NF-κB signal transduc-
tion pathway [14]. In accordancewith this, Staels and coworkers reported
in vivo anti-inﬂammatory actions of PPARα agonists, resulting in de-
creased interleukin-6 (IL-6) production in hyperlipidemic patients [15].
The aim of the present studywas to probe a potential contribution of
disturbed UPS in the development of lipid-driven cardiomyopathy.
Furthermore, we wanted to clarify if cardiac oxidative inﬂammatory
stress and defective PPARα signaling are linked in ATGL deﬁciency.
2. Materials and methods
2.1. Mice and experimental groups
Homozygous male and female AKO mice on a C57BL/6 background
(n = 30–50) and their corresponding wild-type (WT; n = 30–50) lit-
termates were used in this study. Additionally, WT (n = 15–25) and
AKO (n = 15–25) mice with cardiomyocyte-directed overexpression
of ATGL driven by the α-myosin heavy chain promoter were used in a
subset of experiments and were herein designated as WT/cTg and
AKO/cTg, respectively. AKO mice [11] as well as cardiac transgene
mice [9] were generated in the laboratory of Rudolf Zechner (University
of Graz, Austria). After weaning, mice were kept on standard laboratory
chow and were allowed ad libitum access to food and water. Animals
were housed in approved cages and kept on a regular 12 h dark/light
cycle. At the age of 9–10 weeks, mice were sacriﬁced and hearts were
dissected, cleaned and stored in liquid nitrogen until further analysis.
Animal carewas in compliancewith the Austrian law on experimen-
tationwith laboratory animals (last amendment, 2011) based on the US
National Institutes of Health guidelines.
2.2. Wy14,643 treatment
WT and AKO animals (aged 6–7 weeks; 5–8 animals per group)
were fed chow mixed with 0.1% Wy14,643 (Cayman Chemical, Ann
Arbor, MI, USA) for threeweeks [9,12]. Food intakewas similar betweenthe experimental groups. The protocol was approved by the Austrian
Federal Ministry of Science and Research (BMWF-66.007/0001-11/
3b/2014).
2.3. Real-time PCR
Total RNA was extracted from homogenized cardiac tissues using
the GenElute™ Mammalian Total RNA Miniprep Kit including DNAse
treatment of samples (Sigma, Austria). For ﬁrst-strand cDNA synthesis,
~800 ng of total RNA was reversely transcribed at 37 °C using the High
Capacity Reverse Transcription Kit (Life Technologies, Vienna, Austria).
Real-time PCR analysis was performed with ~30 ng cDNA using
TaqMan® Universal PCR Master Mix and pre-designed TaqMan® Gene
Expression Assays as listed in Supplementary Table 1. Ampliﬁcation
was carried out using 7300 Real-Time PCR System (Life Technologies,
Vienna, Austria). Cycling conditions were as follows: 2 min at 50 °C,
10 min at 95 °C, 40–50 cycles of 15 s at 95 °C, and ﬁnally 1 min at
60 °C. Relative mRNA levels were quantiﬁed using the 2−ΔΔCt method,
normalized to the reference gene cyclophilin.
2.4. Western blot analysis
Heartswere homogenized in 10 volumes of ice-cold RIPA lysis buffer
(Sigma, Vienna, Austria) containing 0.5mMethylenediaminetetraacetic
acid (EDTA), protease and phosphatase inhibitor cocktails (Complete™;
PhosSTOP™; Roche, Vienna, Austria) using a glass potter Elvehjem
homogenizer. Protein concentration was determined with the Thermo
Scientiﬁc Pierce BCA™ Protein Assay Kit (Fisher Scientiﬁc Austria
GmbH, Vienna, Austria) using bovine serumalbumin as standard. Dena-
tured proteins (20–40 μg) were resolved by SDS-PAGE (Mini-PROTEAN
T, Bio-Rad) and transferred onto nitrocellulose membranes (0.45 μm).
After blocking with 5% non-fat dry milk in Tris-buffered saline contain-
ing 0.1% (v/v) Tween-20 for 1 h at ambient temperature, membranes
were incubated overnight at 4 °C with primary antibodies (listed in
Supplementary Table 2). Thereafter, membranes were washed 3 times
for 5 min and incubated with respective horseradish peroxidase-
conjugates anti-rabbit or anti-mouse IgG (1:5,000). Immunoreactive
bands were visualized with ECL detection reagent (Biozym, Germany)
and quantiﬁed densitometrically using the E.A.S.Y. 1.3 Win 32 software
(Herolab, Vienna, Austria).
2.5. Measurement of chymotrypsin-like proteasomal activity
Hearts were homogenized in 50 mM Tris buffer, pH 7.5, containing
20 mM KCl, 5 mM MgCl2, 250 mM sucrose, and 1 mM dithiothreitol
using a glass potter Elvehjem homogenizer. Homogenates were cen-
trifuged at 20,000 g for 15 min at 4 °C. Lipid-free infranatants were
collected and protein concentration was determined with the Thermo
Scientiﬁc Pierce BCA™ Protein Assay Kit (Fisher Scientiﬁc Austria
GmbH, Vienna, Austria) using bovine serum albumin as standard.
Samples containing 30–50 μg protein were incubated in 100 μl of
50 mM Tris buffer (pH 7.5), containing 20 mM KCl, and 5 mM MgCl2,
in the presence and absence of 1 μMMG132 (Enzo; Switzerland). The
peptide substrate SucLLVY-AMC (Sigma, Austria) was used at a concen-
tration of 100 μM. Assays were carried out in 96 well microtiter plates
and ﬂuorescence was measured after 10 min incubation at 37 °C using
a ﬂuorescence plate reader (excitation wavelength of 355 nm, emission
wavelength of 460 nm; SpectraMax, Molecular Devices, Germany).
Chymotrypsin-like activity was quantiﬁed and expressed as cleaved
AMC per mg protein using AMC (Sigma, Austria) as a standard.
2.6. Measurement of NADPH oxidase activity
Frozen hearts were homogenized in 10 volumes of PBS containing
Complete™ using a glass potter Elvehjem homogenizer. Total ho-
mogenates (~100 μg protein) were incubated in PBS containing
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the absence or presence of Cu,Zn-superoxide dismutase (SOD-1;
500 U/ml). Thereafter, NADPH (300 μM) was added to activate
NADPH oxidases, followed by addition of lucigenin at a non-redox
cycling concentration of 5 μM [16]. Lucigenin-derived chemilumi-
nescence was measured every 30 s for 5 min using a TriCarb®
2100TR Liquid Scintillation Counter (PerkinElmer, Vienna, Austria).Fig. 1. UPS and cardiac ATGL deﬁciency. (A) Representative Western blots of ATGL protein expr
posure timeswere chosen to better illustrate supraphysiological ATGL levels in transgene anim
as UBE1a protein expression inWT, AKO,WT/cTg, and AKO/cTg hearts. (C) Accumulation of ub
bars),WT/cTg (striped bars), andAKO/cTg (gray bars)mice. Total proteinubiquitinationwas sig
experiments. (D) Protein expression of UBE1a was upregulated in AKO hearts. Data were expre
experiments. (E) Chymotrypsin-like proteasomal activitywasmeasured in cardiac cytosols ofW
Chymotrypsin-like activitywas inhibited in the presence of the peptide aldehydeMG132 (1 μM)
similar activation proﬁle. Data represent mean values ± S.E.M. of 5–6 individual experiments;
ATGL deﬁciency. (H) Cardiac homogenates of AKOmice showed decreased expression ofmitoch
WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments; *p b 0Results were corrected for protein-deﬁcient blanks and expressed
as cpm per μg protein.
2.7. Statistics
Results were expressed as mean values ± S.E.M. Comparison
between2 groupswas performed using Student's t-test and comparisonession in cardiac homogenates ofWT, AKO,WT/cTg, and AKO/cTg mice. Two different ex-
als. (B) RepresentativeWestern blots showing total levels of ubiquitinated proteins as well
iquitinated proteins was quantiﬁed in cardiac homogenates of WT (open bars), AKO (solid
niﬁcantly increased inATGL deﬁciency.Data representmean values±S.E.M. of 9 individual
ssed as folds of WT control (WT= 1) and represent mean values ± S.E.M. of 6 individual
T (open circles) andAKO (solid circles)mice over a range of ATP concentrations (0–4mM).
. (F) Normalization of proteasomal activity to basal values (basal activity=1) resulted in a
*p b 0.05 vs WT. (G) Protein expression of the 19S regulatory subunit was not affected by
ondrial marker proteins citrate synthetase and prohibitin. Data were expressed as folds of
.05 vs WT.
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Student–Newman–Keuls as post-hoc test. p-Values of b0.05 were
considered as statistically signiﬁcant.
3. Results3.1. Accumulation of ubiquitinated proteins in cardiac ATGL deﬁciency
Fig. 1A shows a representative Western blot of ATGL expression in
cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg mice. Two
different exposure times were chosen to better illustrate the massive
ATGL overexpression in transgene animals (WT/cTg and AKO/cTg). To
examine the involvement of UPS in the pathogenesis of cardiac dysfunc-
tion observed in AKOmice, total levels of ubiquitinated proteins as well
as protein expression of the ubiquitin-activating enzyme E1 (UBE1a)
were measured in cardiac homogenates of WT, AKO, WT/cTg, and
AKO/cTgmice (Fig. 1B). As shown in Fig. 1C, homogenates of AKO hearts
showed markedly increased levels of ubiquitinated proteins, whereas
only minor accumulation was observed in WT/cTg and AKO/cTg mice
compared to WT controls (Fig. 1C). Protein expression of UBE1a,
which catalyzes the initial step of the UPS cascade (i.e. activation of
ubiquitin moieties through thioester formation), was more than 2-fold
increased in AKO hearts (Fig. 1D). Expression of UBE1a was normalized
to WT levels upon cardiomyocyte-directed overexpression of ATGL in
AKO mice. To investigate whether increased protein ubiquitination
was a consequence of 26S proteasomal dysfunction, chymotrypsin-
like activity was measured in cardiac cytosols of WT and AKO animals.
Peptidase activity was monitored over a range of ATP concentrations
(0–4 mM) to ensure maximal activation of the 26S proteasome. ATP
bidirectionallymodulated proteasomal activitywithmaximal activation
observed at 10–30 μM ATP (Fig. 1E). Normalizing proteasomal activity
to basal values (measured in the absence of exogenous ATP) resulted
in a similar activation proﬁle of the UPS in cardiac homogenates of WT
and AKO mice (Fig. 1F). The selective proteasome inhibitor MG132
(1 μM) decreased chymotrypsin-like activity to a similar extent
(~90%) in WT and AKO animals (Fig. 1E). Protein expression of the
19S regulatory capwas not affected by ATGL deﬁciency (Fig. 1G). West-
ern blot analysis of the mitochondrial marker citrate synthetase
revealed that protein expression was signiﬁcantly decreased in AKO
animals by 41 ± 8%. Similar results were obtained for prohibitin
(53 ± 18%), however, results failed to reach statistical signiﬁcance
(Fig. 1H).3.2. Endoplasmic reticulum (ER) stress and apoptosis
Dysfunction of the proteasome and subsequent accumulation of
damaged/misfolded proteins have been described to cause an ER-
resident complex cellular stress response termed as unfolded protein
response (UPR; for review, see [17]). To judge if activated UPR is opera-
tive in cardiac ATGL deﬁciency we measured protein/mRNA expression
of selected parameters of the system. Western blot analysis of cardiac
homogenates showed that protein expression of glucose-regulated pro-
tein 78 kDa (GRP78; Fig. S1A), activating transcription factor 6 (ATF6;
Fig. S1B), and inositol-requiring kinase 1 (IRE1; Fig. S1C)was not affect-
ed by ATGL deﬁciency, arguing against an involvement of ER stress in
cardiac dysfunction of AKO mice. Interestingly, protein expression of
the ER-resident chaperon protein disulﬁde isomerase (PDI) was elevat-
edmore than 6-fold in AKOhearts and normalized upon overexpression
of ATGL in AKOcardiomyocytes (Fig. S1D). Cardiac protein expression of
the proapoptoticmarker C/EBP homologous protein (CHOP)was similar
in all experimental groups (Fig. S1E). Representative Western blots are
shown in Fig. S1F. To test if UPS dysfunction is linked to an imbalance of
apoptosis regulating stimuli, protein expression of pro-apoptotic p53
and anti-apoptotic Bcl-2 was measured in cardiac homogenates of WT,AKO, WT/cTg, and AKO/cTg animals. As shown in Figs. S1G and 1H,
neither protein expression of p53 nor of Bcl-2 was signiﬁcantly affected
by ATGL knockout.
3.3. Activation of the NF-κB pathway in ATGL deﬁciency
To investigate the mechanism underlying cardiac inﬂammation in
ATGL deﬁciency [13] we analyzed crucial parameters of canonical NF-
κB signaling (for review, see [18]). As illustrated in Fig. 2A, cardiac
ATGL deﬁciency led to increased protein expression of the IκB kinase
(IKK) complex as IKKα protein levels were signiﬁcantly elevated in
homogenates of AKO mice. By contrast, IKKβ protein expression was
similar in all experimental groups (Fig. 2B). Furthermore, AKO hearts
showed a more than 3-fold increased NF-κB RelA/p65 protein expres-
sion that was normalized to WT levels in hearts of AKO/cTg mice
(Fig. 2C). Phosphorylation of NF-κB RelA/p65 at serine 536, which is
thought to activate the NF-κB complex independently of IκB release
[19], was also markedly elevated in AKO hearts (Fig. 2D). However,
the ratio of phosphorylated to total NF-κB protein was unaffected by
ATGL knockout (data not shown). Cardiac protein levels of IκB (which
reactswithNF-κB to form an inactive cytosolic complex)were increased
nearly 2-fold in AKOmice (Fig. 2E). All markers of NF-κB signaling that
were increased in AKOmice were restored in AKO/cTg mice. Represen-
tative Western blots are shown in Fig. 2F. Activation of cardiac NF-κB
signaling was supported by qPCR experiments showing that mRNA
levels of selected NF-κB target genes including TNFα, monocyte
chemoattractant protein-1 (MCP-1), IL-6, heme oxygenase-1 (HO-1),
and GTP cyclohydrolase 1 (GTPCH-1) were signiﬁcantly increased in
AKO hearts (Fig. 2G).
3.4. Treatment of WT and AKO mice with the PPARα agonist Wy14,643
Since chronic treatment of AKOmice with PPARα agonists has been
described to substantially improve cardiac performance in prior studies
[9,12], we investigated whether the drug has a similar effect on cardiac
proteasomal function. For this purpose, 6-week-old WT and AKO
mice were fed a chow containing 0.1% Wy14,643 according to a well-
established protocol [9]. To evaluate the outcome of the treatment,
cardiac mRNA expression of PPARα coactivator PGC-1α (Fig. 3A) and
mitochondrial transcription factor A (Tfam; Fig. 3B) was analyzed.
Both, PGC-1α and Tfam mRNA were signiﬁcantly decreased in ATGL-
deﬁcient hearts (Figs. 3A and B) by 52± 16% and 30± 4%, respectively.
Chronic treatment with the PPARα agonist Wy14,643 restored PGC-1α
and Tfam mRNA levels in AKO animals to WT niveau. These results are
in good accordance with that reported by Haemmerle and colleagues
[9]. As shown in Figs. 3C and D, feeding of AKO mice with the PPARα
agonist reduced cardiac protein expression of ubiquitinated proteins
to WT levels suggesting restored function of the UPS in those hearts.
To investigate whether the observed effect was linked to altered NF-
κB activation we analyzed protein expression and phosphorylation sta-
tus of NF-κB RelA/p65. As illustrated in Figs. 3E and F, both parameters
were reduced to WT levels upon Wy14,643 treatment. In contrast,
cardiac IκB protein expression was not normalized upon feeding mice
with the PPARα agonist (Fig. 3G). Furthermore, we observed that
mRNA expression of inﬂammatory markers TNFα (Fig. 3H) and MCP-1
(Fig. 3I) were reduced to WT levels while increased expression of pro-
tective HO-1 persisted after Wy14,643 treatment (Fig. 3J).
3.5. Cardiac oxidative stress and Wy14,643 treatment
Cardiac oxidative stress was assayed as mRNA expression of the
two major cardiac NADPH oxidase isoforms (NOX), NOX2 and NOX4,
as well as protein expression of the NOX2 cytosolic activator subunits
p47phox and p67phox. As shown in Fig. 4A, NOX2mRNAwas signiﬁcantly
upregulated in AKO animals. This effect was signiﬁcantly decreased in
AKO animals treated with the PPARα agonist Wy14,643. In contrast,
Fig. 2. Activation of NF-κB signaling in AKO hearts. Protein expression was measured in cardiac homogenates of WT (open bars), AKO (solid bars), WT/cTg (striped bars), and AKO/cTg
(gray bars) mice. Protein levels of (A) IKKα but not of (B) IKKβ were signiﬁcantly increased in ATGL deﬁciency. Protein expression of (C) NF-κB, (D) p-NF-κB and (E) IκB were raised
in AKO hearts. Data were expressed as folds of WT control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments; *p b 0.05 vs WT; #p b 0.05 vs AKO.
(F) Representative Western blots. (G) Cardiac mRNA levels of NF-κB target genes TNFα, MCP-1, IL-6, HO-1, and GTPCH-1 determined by qPCR were upregulated in ATGL deﬁciency.
Data represent mean values ± S.E.M. of 5–10 individual experiments. *p b 0.05 vs WT.
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treatment (Fig. 4B). In accordance with NOX2 mRNA levels, p47phox
protein showed an ~8-fold upregulation in cardiac homogenates of
AKO mice. Upon Wy14,643 treatment, protein expression of p47phox
was signiﬁcantly reduced compared to untreated AKOs but was still
~6-fold increased compared to WT controls (Fig. 4C). By contrast, ~8-
fold increased protein expression of p67phox observed in AKO hearts
persisted upon Wy14,643 treatment (Fig. 4D). To test for the anti-
oxidative capacity, catalase and SOD-1 protein expression was mea-
sured in cardiac homogenates of WT, AKO, WT/cTg, and AKO/cTg
mice. SOD-1 proteinwas signiﬁcantly decreased in AKO hearts, an effect
that was not affected by Wy14,643 treatment (Fig. 4E). Proteinexpression of catalase, which triggers decomposition of hydrogen per-
oxide, was similar in all experimental groups (Fig. 4F). To investigate if
partially reduced mRNA and protein levels of distinct NOX subunits
have an impact on NADPH oxidase activity, lucigenin-derived chemilu-
minescence was measured in cardiac homogenates of untreated and
Wy14,643-supplemented animals. As shown in Fig. 4G, ATGL deﬁciency
resulted in more than 3-fold higher chemiluminescence production
compared toWT. Treatment with the PPARα agonist Wy14,643 signiﬁ-
cantly reversed the effect of ATGL deﬁciency. Preincubation with the
superoxide scavenging enzyme SOD-1 diminished chemiluminescence
in all experimental groups to an equal extent (56 ± 2.6%). Representa-
tive Western blots are illustrated in Fig. 4H.
Fig. 3. Feeding of WT and AKO mice with the PPARα agonist Wy14,643. Protein and mRNA expression was measured in cardiac homogenates prepared fromWy14,643-treated WT
(striped bars) and AKO (gray bars) mice and compared to that of non-treated WT (open bars) and AKO (solid bars) controls. Improvement of PPARα signaling by Wy14,643 treatment
was conﬁrmed by reversal of (A) PGC-1α and (B) TfammRNA expression. Feeding of AKOmice withWy14,643 reduced cardiac expression of (C, D) ubiquitinated proteins toWT levels.
Protein expression of (E) NF-κB and (F) p-NF-κB but not (G) IκBwas reversed inWy14,643-treated AKOmice. CardiacmRNA levels of theNF-κB target genes (H) TNFα and (I)MCP-1were
reduced to WT levels while increased expression of (J) HO-1 persisted after Wy14,643 treatment. Data represent mean values ± S.E.M. of 5–6 individual experiments. *p b 0.05 vs WT;
#p b 0.05 vs AKO.
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UPS-mediated protein degradation is crucial tomaintain the dynam-
ic equilibrium between intact and misfolded/damaged proteins. In
cardiomyocytes, which are exposed to heavymechanical workload, im-
balances between protein biosynthesis and degradation were reported
to contribute to cardiac diseases including desmin-related cardiomyop-
athy, cardiac hypertrophy, and heart failure [2,4,6].
In the present study we demonstrate that AKO mice suffer from
signiﬁcant disturbances in cardiac UPS that are associated with marked
activation of cellular NF-κB signaling. Chronic treatment of mice with
the PPARα agonist Wy14,643 improved proteasomal function and
prevented NF-κB activation and associated oxidative inﬂammatory
stress.
The observation that accumulation of ubiquitinated proteins was
completely reversed by cardiomyocyte-directed overexpression ofATGL suggests a causal relationship between ATGL deﬁciency and
dysfunction of the UPS. Increased protein ubiquitination may arise
from defective proteasomal activity on the one hand and accumulation
of oxidatively damaged, misfolded and/or aggregated proteins on the
other hand. Despite decreased basal proteasomal activity in AKO hearts,
ATP-dependent activation was similar between WT and AKO hearts,
suggesting that maximal stimulation of the 26S proteasome is still
preserved. According to Powell and coworkers, the 19S regulatory cap,
which facilitates substrate access to the 20S catalytic core in an ATP-
dependent manner, may represent a potential target of oxidative mod-
iﬁcation [20]. However, our results show that protein expression of the
19S particle was not affected by ATGL deﬁciency. Nevertheless we
cannot exclude oxidative damage of distinct ATPase subunits within
the 19S complex.
Haemmerle and coworkers demonstrated that AKO hearts suffer
from prominentmitochondrial dysfunction evident as impaired oxygen
Fig. 4.Oxidative stress inWy14,643-treated AKOmice. CardiacmRNA expressionwasmeasured inhomogenates ofWT(open bars), AKO (solid bars),Wy14,643-treatedWT (striped bars),
and Wy14,643-treated AKO/cTg (gray bars) mice. (A) NOX2 mRNA was signiﬁcantly upregulated in AKO animals. This effect was decreased by treatment with the PPARα agonist
Wy14,643. (B) Upregulation of NOX4 mRNA in AKO animals persisted uponWy14,643 supplementation. (C) Protein expression of p47phox was signiﬁcantly increased in cardiac homog-
enates of AKOmice and reduced by 25% uponWy14,643-treatment. (D) Upregulation of cardiac p67phox protein expressionwas unaffected byWy14,643. (E, F) Protein expression of SOD-
1 was signiﬁcantly decreased in untreated andWy14,643-treated AKO hearts, while cardiac levels of catalase were similar in all experimental groups. Data were expressed as folds ofWT
control (WT = 1) and represent mean values ± S.E.M. of 6 individual experiments; *p b 0.05 vs WT; #p b 0.05 vs AKO. (G) NADPH oxidase activity was measured as lucigenin-derived
chemiluminescence. (H) Representative Western blots.
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Mitochondrial defects are often associated with decreased ATP levels
[21]. Since ATP is required for proteasomal assembly and protein
processing of the 26S proteasome (for review, see [22]), it is conceivable
that low intracellular ATP levels in AKO hearts might be an explanation
for insufﬁcient basal proteasomal activity. This hypothesis is corrob-
orated by the observation that PPARα treatment normalized both
cardiac protein ubiquitination (this study) and mitochondrial func-
tion [9]. Additionally, decreased expression of the mitochondrial
marker proteins citrate synthetase (and prohibitin) point to reduced
mitochondrial content/function in AKO hearts and therefore imply
potential differences in endogenous ATP production between WT
and AKO hearts.
Considering the fact that AKO mice suffer from oxidative inﬂamma-
tory stress [13], oxidative modiﬁcation of a crucial site within theproteasome is feasible. This hypothesis is supported by a recent study
of coronary I/R injury, in which decreased proteasomal trypsin-like
activity was linked to oxidative modiﬁcation of the proteasome [23].
Chronic treatment of AKO mice with the PPARα agonist Wy14,643
resulted in reduced NADPH oxidase activity which together with
rescued cardiac protein ubiquitination argues for a link between oxida-
tive stress and UPS dysfunction. In accordance with our study, Barlaka
and colleagues demonstrated that Wy14,643 treatment ameliorated
parameters of cardiac I/R injury by reduction of oxidative stress and
inhibition of matrix metallopeptidases [24]. In a separate study, Powell
and colleagues showed that cardiac I/R injury was accompanied by
decreased proteasomal activity and subsequent increase in myocardial
ubiquitinated proteins [5,20]. It is therefore feasible that in the AKO
model Wy14,643 exerts its beneﬁcial effect by decreasing oxidative
stress and therefore normalizing proteasomal activities.
18 M. Mussbacher et al. / Journal of Molecular and Cellular Cardiology 77 (2014) 11–19Proteasomal dysfunction in AKO hearts seems accompanied by up-
regulation of the E1/E2/E3 machinery since protein expression of
UBE1a (which initiates activation of ubiquitin) was signiﬁcantly
increased in AKO hearts. This observation agrees well with reports of
increased mRNA expression of the ubiquitin-conjugating enzyme
E2G2 observed in human failing hearts [25]. Therefore, it is conceivable
that potential compensating mechanisms exist within cells that coun-
teract the increased burden of damaged/misfolded proteins.
Analysis of selected targets of the cellular UPR revealed that protein
expression of the ER chaperon PDI (which catalyzes formation and rear-
rangement of disulﬁde bonds) wasmarkedly increased in AKOhearts. A
recent study suggests a protective role of PDI in the myocardium of
infarct patients since its expression was inversely correlated with apo-
ptotic rates and presence of heart failure [26]. Furthermore, increased
activity of superoxide dismutase in PDI-overexpressing cardiomyocytes
was observed. Therefore, upregulated PDI protein in AKOmice appears
to bemore related to oxidative stress than to UPR activation [26]. In line
with this, we observed similar expression levels of the pro-apoptotic
transcription factors CHOP and p53 in WT and AKO hearts, arguing
against an apoptotic scenario in cardiac ATGL deﬁciency. We therefore
conclude that PDI is upregulated to preserve proper protein folding
and thereby reduce working load of the UPS. This is in agreement
with observations from Fuchs and colleagues, showing a protective
role of ATGL in tunicamycin-induced hepatic ER stress [27].
The observation of enhanced NF-κB p65 signaling in cardiac ATGL
deﬁciency is in line with the idea that chronic activation of NF-κB
signaling promotes inﬂammatory processes and hypertrophic growth
of cardiomyocytes [28]. Our data point to another less describedScheme 1. Interplay of signaling pathways leading to cardiac dysfunction. ATGL deﬁciency i
Consequent mitochondrial dysfunction results in decreased intracellular ATP levels, leading to
mulation and aggregation of ubiquitinated proteins. Increased oxidative inﬂammatory stress m
Damaged and/ormisfolded proteins impair proteasomal activity by saturation of the 20S corew
oxidative inﬂammatory stress, improves mitochondrial function, and consequently increases Uimplication of NF-κB in the development of cardiac heart failure, that
is NF-κB-mediated oxidative inﬂammatory stress as pivotal step leading
to accumulation of ubiquitinated proteins. A similar correlation was
suggested by Marfella and colleagues [34], who provided evidence for
an important role of the UPS in NF-κB-dependent inﬂammation in ath-
erosclerotic plaques of hypertensive patients. In this context, it is also
conceivable that the beneﬁcial effects of Wy14,643 treatment on oxida-
tive inﬂammatory stress in AKO animalsweremediated via inhibition of
the inﬂammatory actions of NF-κB.
Our current working hypothesis is depicted in Scheme 1. ATGL deﬁ-
ciency in cardiomyocytes results in massively reduced triacylglyceride
hydrolysis and consequently decreased production of lipid ligands
for PPARα activation (e.g. fatty acids, acyl-CoA and various fatty
acid-derived compounds) [9]. As PPARα signaling is an important
key player in energy metabolism and inﬂammation, its downregula-
tion leads to deleterious consequences such as disrupted mitochon-
drial substrate oxidation and consequent decreased ATP production.
Since ATP is required for 19S-mediated channel opening and sub-
strate unfolding, limited ATP availability causes decreased activation
of the 26S proteasome (path 1). Proteasomal dysfunction entails
insufﬁcient degradation of target proteins, thus resulting in accumu-
lation and aggregation of ubiquitinated products. In a circulus
vitiosus, these aggregates further inhibit proteasomal activities,
which causes additional cellular stress [29]. Considering the pres-
ence of oxidative inﬂammatory stress in AKO animals, disturbances
of the cardiac UPS might also originate from oxidative modiﬁcations
of critical residues within the catalytic core of the proteasome (path
2). Recent studies have shown that distinct subunits are susceptiblen cardiomyocytes results in decreased production of lipid ligands for PPARα activation.
reduced activation of the 26S proteasome (path 1). Proteasomal dysfunction causes accu-
ay damage critical residues/domains within the catalytic core of the proteasome (path 2).
ith non-degradable aggregates (path 3). Restored PPARα signalingwithWy14,643 reduces
PS activity and cardiac performance.
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mediated alkylation, and S-glutathionylation [23,30–32]. In addition,
enhanced superoxide production may also cause protein crosslinking
through formation of Schiff bases and/or disulﬁde bridges [33] which
might lead to saturation of the proteasome by non-degradable aggre-
gates (path 3). Defective proteasomal activity together with mito-
chondrial dysfunction is implicated in the development of cardiac
dysfunction and premature death of AKO animals. Pharmacological in-
tervention with the PPARα agonist Wy14,643 improves mitochondrial
and proteasomal functions aswell as oxidative and inﬂammatory stress.
In summary, our data demonstrate pronounced accumulation of
ubiquitinated proteins in hearts of AKOmice, associatedwith decreased
basal chymotrypsin-like proteasomal activity. These effects were
accompanied bymitochondrial dysfunction and inﬂammatory oxidative
stress. Chronic treatment with the PPARα agonist Wy14,643 reversed
proteasomal dysfunction and reduced oxidative and inﬂammatory
stress in AKO mice. Our data point to a hitherto unrecognized link
between proteasomal function, PPARα signaling and inﬂammatory
oxidative stress in cardiovascular disease.
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